Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Renal Dialysis
Pervasis Therapeutics' Vascugel initiates U.S. clinical trials
October 25th, 2006
Pervasis Therapeutics, Inc. has been enrolling patients in two Phase I clinical trials of the company's first product, Vascugel, to evaluate its safety and feasibility for the maintenance of vascular patency after creation of arteriovenous (AV) access graft and AV fistula, respectively, for patients undergoing dialysis for the treatment of end-stage renal disease (ESRD).
The company's investigational new drug (IND) application was successfully reviewed by the U.S. Food and Drug Administration (FDA) in May.
Vascugel is a novel allogeneic cell therapy product that restores natural repair and regeneration pathways in the vasculature. Extensive...
Source: Biotech Week (2006-10-25)
|
